文献速递其他结缔组织病血管炎

系统性硬化症相关肺动脉高压伴或不伴间质性肺病的治疗及其对生存的影响:德国系统性硬化症网络大型队列研究

Treatment of systemic sclerosis-associated pulmonary hypertension with and without interstitial lung disease and its impact on survival: a large cohort study of the German network for systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该研究基于德国系统性硬化症网络(DNSS)注册队列,纳入384例新发肺动脉高压(PH)的系统性硬化症(SSc)患者,其中271例(70.6%)合并间质性肺病(ILD)。分析显示,无论是否合并ILD,PH单药与联合治疗组间的生存率均无显著差异(P=0.197),且不同治疗策略对伴或不伴ILD的PH患者生存均无显著影响。

要点

  • SSc-PH患者中70.6%合并ILD,ILD患者肺功能指标显著更低。
  • PH单药与联合治疗组间生存率无显著差异(P=0.197)。
  • 无论是否合并ILD,不同治疗策略均未显著影响生存。

核心结论

  • 在德国,合并ILD的新发PH的SSc患者常接受PH联合治疗,该策略似乎可行且不恶化生存,前提是ILD不严重。

研究设计与样本

  • 基于德国系统性硬化症网络(DNSS)注册队列的回顾性队列研究,纳入6003例注册患者中注册后新诊断PH的SSc患者,最终384例符合标准,其中271例(70.6%)合并ILD。

主要发现

  • 随访期间,伴或不伴ILD的PH患者用力肺活量(FVC)和一氧化碳弥散量(DLCO)均数值下降,且ILD患者显著更低(随访期间最小FVC均值70.79±24.36%)。
  • 伴与不伴ILD的PH患者在PH治疗类别(单药、双药或三药)分布上无显著差异(P=0.865)。
  • PH单药治疗组与联合治疗组间未观察到生存差异(P=0.197)。
  • 亚组分析表明,无论是否存在ILD,不同治疗策略均未显著影响PH患者的生存结局。

临床怎么用

  • 对于不伴严重ILD的SSc相关PH患者,采用PH联合治疗是可行的,且不增加死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to analyse survival in SS-associated pulmonary hypertension (SSc-PH) patients with or without interstitial lung disease (ILD) stratified by PH monotherapy and PH combination therapy, respectively. METHODS: Among the 6003 patients registered with the German Network for Systemic Sclerosis (DNSS) registry, SSc patients with incident PH diagnosed after registry entry were included. Kaplan-Meier analysis was performed to estimate the overall survival, and the log-rank test was used to assess differences between groups stratified by the presence of ILD or PH treatment. RESULTS: Of, the 384 patients who fulfilled the inclusion criteria, 271 had concomitant ILD (70.6%). The mean follow-up period was 8.69 ± 4.94 years. Forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) numerically decreased in PH patients with and without ILD and were significantly lower in patients with ILD (mean value of minimal FVC during follow-up: 70.79 ± 24.36%). There was no significant difference in the distribution of PH therapy categories (mono, dual, or triple therapy) between PH patients with and without ILD involvement (P = 0.865). No survival difference was observed between the monotherapy and combination therapy groups (P = 0.197). Subgroup analysis indicated that varying the treatment strategies did not significantly impact the survival outcomes of PH patients, whether or not ILD was present. CONCLUSION: SSc patients with ILD and incident PH are often treated with PH combination therapy in Germany. This treatment strategy seems feasible and does not worsen survival in PH patients, provided that ILD is not severe.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Schmalzing M, Moinzadeh P, Weliwitage J, et al. Treatment of systemic sclerosis-associated pulmonary hypertension with and without interstitial lung disease and its impact on survival: a large cohort study of the German network for systemic sclerosis. Rheumatology (Oxford). 2026. PMID: 41987563. doi:10.1093/rheumatology/keag155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。